Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib

Leukemia. 2022 Aug;36(8):2129-2131. doi: 10.1038/s41375-022-01640-y. Epub 2022 Jul 16.

Authors

Affiliations

¹ Division of Hematology, The Ohio State University, Columbus, OH, USA.
² Department of Internal Medicine, The University of Cincinnati, Cincinnati, OH, USA.
³ Division of Hematology, The Ohio State University, Columbus, OH, USA. [email protected].

PMID: 35842461
DOI: 10.1038/s41375-022-01640-y

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Letter

MeSH terms

Adenine / analogs & derivatives
Disease-Free Survival
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Piperidines
Progression-Free Survival
Treatment Outcome

Substances

Piperidines
ibrutinib
Adenine

Grants and funding